Ranolazine vs Isosorbide Dinitrate for Managing Angina
Introduction to Angina Management
- The American College of Cardiology recommends ranolazine for patients with chronic stable angina who cannot tolerate or have inadequate symptom control with first-line agents like isosorbide dinitrate, particularly in cases of bradycardia, hypotension, or in patients with diabetes 1, 2
Mechanism of Action and Hemodynamic Effects
- Isosorbide dinitrate acts as a nitric oxide donor causing vasodilation of coronary and peripheral vessels, reducing preload and afterload, thereby decreasing myocardial oxygen demand 3
- Ranolazine works through inhibition of late sodium current (late INa), preventing intracellular calcium overload during ischemia without significantly affecting hemodynamic parameters 1, 4
- Isosorbide dinitrate causes significant reduction in blood pressure 2
- Isosorbide dinitrate produces reflex tachycardia 2
- Ranolazine has minimal to no effect on blood pressure or heart rate 1, 2, 4
Clinical Efficacy and Special Populations
- Isosorbide dinitrate is particularly effective in vasospastic angina 3
- Ranolazine extended-release formulation (500-1000 mg) effectively reduces symptoms of chronic stable angina 1, 2
- Ranolazine may be more effective in patients with left ventricular hypertrophy 1, 2
- Ranolazine reduces HbA1c levels in diabetic patients with angina 1, 2, 4
Safety Profile and Contraindications
- Ranolazine causes dose-related QT interval prolongation 1, 2, 4
- Isosorbide dinitrate may cause headache, dizziness, and hypotension 3
- Tolerance develops with continuous use of isosorbide dinitrate 3
- Isosorbide dinitrate is contraindicated with PDE-5 inhibitors due to risk of severe hypotension 3